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Opiate analgesia in the spinal cord is impaired in diabetic neuropathic pain (DNP), but
until now the reason is unknown. We hypothesized that it resulted from a decreased
inhibition of substance P (SP) signaling within the dorsal horn of the spinal cord.
To investigate this possibility, we evaluated the effects of endomorphin-2 (EM2), an
endogenous ligand of the µ-opioid receptor (MOR), on SP release within lamina I of
the spinal dorsal horn (SDH) in rats with DNP. We established the DNP rat model
and compared the analgesic efficacy of EM2 between inflammation pain and DNP
rat models. Behavioral results suggested that the analgesic efficacy of EM2 was
compromised in the condition of painful diabetic neuropathy. Then, we measured
presynaptic SP release induced by different stimulating modalities via neurokinin-1
receptor (NK1R) internalization. Although there was no significant change in basal and
evoked SP release between control and DNP rats, EM2 failed to inhibit SP release by
noxious mechanical and thermal stimuli in DNP but not in control and inflammation pain
model. We also observed that EM2 decreased the number of FOS-positive neurons
within lamina I of the SDH but did not change the amount of FOS/NK1R double-
labeled neurons. Finally, we identified a remarkable decrease in MORs within the
primary afferent fibers and dorsal root ganglion (DRG) neurons by Western blot (WB)
and immunohistochemistry (IHC). Taken together, these data suggest that reduced
presynaptic MOR expression might account for the loss of the inhibitory effect of EM2 on
SP signaling, which might be one of the neurobiological foundations for decreased
opioid efficacy in the treatment of DNP.
Keywords: endomorphin-2, diabetic neuropathic pain, substance P, neurokinin-1 receptor internalization,
µ-opioid receptor
INTRODUCTION
Diabetic neuropathic pain (DNP) is one of the most prevalent complications of diabetes
mellitus (DM) and takes a heavy toll on physical health and life well-being in DM patients.
DNP management remains a major challenge due to its resistance to traditional opioids
(Mousa et al., 2013; Shaqura et al., 2013). Although patients suffering from DNP could gain pain
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relief from high-dose opioids (Harati et al., 2000; Watson et al.,
2003), the unbearable side-effects, such as sedation, respiratory
depression, tolerance and opioid-induced hyperalgesia (OIH;
Grider and Ackerman, 2008; Zhao et al., 2010), hampered its
clinical application.
Endomorphin-2 (EM2), an endogenous µ-opioid receptor
(MOR) ligand, has shown remarkable analgesic properties and
fewer adverse effects. EM2 overcomes pain by activating pre-
and postsynaptic MORs (Wu et al., 2003; Leng et al., 2005;
Fujita and Kumamoto, 2006; Fichna et al., 2007; Chen Y. B.
et al., 2015) along the spinal nociceptive transmission pathway.
Spinal administration of EM2 has been demonstrated to alleviate
nociceptive behaviors in inflammatory pain (Tateyama et al.,
2002; Zhao et al., 2015), cancer pain (Chen L. et al., 2015) and
peripheral neuropathic pain models (Przewlocka et al., 1999).
However, there are few reports concerning the analgesic effects
of EM2 at the spinal level in the DNP model.
Presynaptic MORs play an important role in opioid analgesia
(Kohno et al., 2005; Chen and Pan, 2006). Opioids inhibit
the release of excitatory neurotransmitters; specifically, the
inhibition of substance P (SP) release is one of the presynaptic
mechanisms for opioid analgesia (Kondo et al., 2005; Chen et al.,
2014). In the neuropathic pain model of chronic constriction
injury (CCI), the loss of inhibition of opioids on SP release within
the spinal dorsal horn (SDH) contributed to the low analgesic
efficacy of opioids (Chen et al., 2014), which was probably
owing to the dysfunctional signaling mechanisms of presynaptic
MORs (Hervera et al., 2011). Additionally, previous data has
suggested that the level of MORs in dorsal root ganglion (DRG)
neurons and the SDH were decreased in DNP rats (Chen et al.,
2002; Mousa et al., 2013; Shaqura et al., 2013, 2014), which
might account for reduced opioid analgesic efficacy. Considering
this, we proposed that the decrease in the inhibitory effects
on presynaptic SP release by opioids might be a potential link
between reduced presynaptic MOR expression and decreased
opioid analgesia in the condition of painful diabetic neuropathy.
Accumulating evidence has suggested that endogenous SP
release can be evoked by noxious stimuli. SP released from
primary afferent terminals activates the neurokinin 1 receptor
(NK1R) in the spinal cord and leads to NK1R internalization
(Trafton et al., 1999, 2001; Trafton and Basbaum, 2000; Kondo
et al., 2005; Chen et al., 2014). In this study, the effects
of EM2 on SP signaling were examined by two postsynaptic
measures of SP release: NK1R internalization to reflect the
amount of functional presynaptic SP release and FOS expression
to examine the activity of NK1R postsynaptic neurons, as
was adopted in previous studies (Trafton et al., 1999; Riley
et al., 2001). In addition, lamina I of the SDH was selected
as the observation zone based on following reasons: first, both
NK1R-like immunoreactive (NK1R-LI) neurons and SP-like
immunoreactive (SP-LI) fibers are densely encountered in
lamina I (Littlewood et al., 1995). Second, NK1R internalization
induced by acute noxious stimuli have been observed mainly in
lamina I (Mantyh et al., 1995; Abbadie et al., 1997; Allen et al.,
1997; Riley et al., 2001). Third, nearly 70% of lamina I neurons
projecting to the parabrachial nucleus express NK1R (Ding et al.,
1995).
The present study aimed at exploring the underlying
mechanisms of decreased analgesic efficacy of EM2 in DNP
disease. Firstly, basal and evoked SP release in control and
DNP rats were compared. Then, the effects of EM2 on
noxious stimulation-induced presynaptic SP release and
FOS expression of postsynaptic NK1R-positive neurons,
that is, the SP signaling within lamina I of the SDH, in
DNP rats were examined. Finally, Western blot (WB) and
immunohistochemistry (IHC) were combined to measure the
expression of MOR in DRG neurons and primary afferent
terminals in the SDH.
MATERIALS AND METHODS
Experimental Animals
Male Sprague-Dawley rats weighing 200–220 g were used in
this study. Before experiments, all animals were adapted to the
experimental circumstances for 5–7 days. All procedures were
approved by the Institutional Animal Care and Use Committee
of the Fourth Military Medical University (Xi’an, P.R. China).
Every measure was taken to minimize the number of animals
and alleviate their discomfort. For the DM model, rats were
given a single intraperitoneal injection of streptozotocin (STZ;
60mg/kg; Sigma-Aldrich, St. Louis, MO, USA) dissolved in 0.1M
ice-cold citrate buffer (pH 4.5). On the third day, blood glucose
values were measured with a glucometer (Accu-Chek Active,
Roche, Basel, Switzerland). Rats with random blood glucose
values higher than 16.7 mmol/L were further used. Age-matched
vehicle rats were used as the control group. For the complete
Freund’s adjuvant (CFA) inflammation model, 100 µl of CFA
(Sigma-Aldrich, St. Louis, MO, USA) was injected into the
subcutaneous surface of the left hindpaw. On the third day, rats
with obvious pathological pain were selected for later behavioral
and morphological studies.
Pain Behavioral Test
All the behavioral tests were performed between 9:00 am and
6:00 pm. Before behavioral testing, animals were habituated in
the testing apparatus for at least 30 min until they calmed down.
For mechanical allodynia, von Frey filaments were applied with
increased forces from 0.4 g to 60.0 g to test the paw withdrawal
threshold (PWT; Morrow, 2004; Cui et al., 2014). Briefly, the von
Frey hairs were pressed vertically on the hind plantar surface for
approximately 4–5 s; each filament was used ten times; and a
5-min interval was left between the different forces. The minimal
force that caused lifting or licking responses at least five times was
considered as the PWT. Thermal hyperalgesia was tested by the
Hargreaves method (Hargreaves et al., 1988;Wu et al., 2014). The
infrared heat was applied to the hind plantar surface to induce
paw withdrawal. The time from initiation of the light beam to
paw withdrawal was recorded from an automated device readout
as paw withdrawal latency (PWL). The intensity of the beam was
set to produce a basal PWL of approximately 14–16 s, and a
cut-off time of 35 s was set to prevent excessive tissue damage.
Each foot was tested four times, and a 10-min interval was left
before the next test.
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Intrathecal Implantation and Drug
Administration
The lumbar catheterization was performed as previously
described (Størkson et al., 1996; Chen et al., 2014). Briefly,
under isoflurane (4%) anesthesia, a midline incision was made
to expose the intervertebral space between L5 and L6. After
a clear exposure, a polyethylene-10 catheter (0.28 mm i.d.
and 0.61 mm o.d., Becton Dickinson, Sparks, MD, USA) was
inserted into the subarachnoid space and pushed rostrally to
terminate at the level of L4–L5 spinal segments. Then the
PE-10 tube was tunneled under the skin and the incisions
were sutured. Three days after catheterization, 10 µl of
lidocaine (2%; followed by 10 µl saline for flushing) was
injected into the catheter to test the successful insertion.
Rats with signs of bilateral hind limbs paralysis immediately
after lidocaine injection were selected for further experiments.
All rats were housed separately to recover for 5–7 days.
The following drugs were administered in this study, EM2
(No. E3148; Sigma-Aldrich), SP (No. 1156; Tocris) and L-
732138, (NK1R antagonist, No. 0868; Tocris). The drugs were
dissolved in sterile saline and administered intrathecally in
a volume of 10 µl solution followed by 10 µl saline for
flushing.
Hindpaw Noxious Stimulation
Both noxious mechanical and thermal stimulation were
employed in this study. The noxious mechanical stimulus
(MS) was applied by clamping the left hindpaw with a
hemostat for 30 s in 4% isoflurane anesthesia. In terms of
nociceptive thermal stimulation, the left hindpaw (below the
ankle joint) was immersed in 50◦C water for 1 min. After
stimulation, anesthesia was stopped and the rats were allowed
to wake. No additional interventions were administrated
to the rats until they were sacrificed. To examine noxious
stimulation-induced NK1R internalization, the rats were
perfused 10 min after the stimulation. To observe double
labeling of NK1R and FOS, the rats were sacrificed 90 min after
the stimulation. For the experiments that evaluated the effects
of EM2 on SP release, EM2 was injected 10 min before the
stimulation.
Immunofluorescent Staining
Rats were deeply anesthetized with 2% sodium pentobarbital
(60 mg/kg, i.p.). When the pain reflex disappeared, 200 ml
of 0.01 M phosphate buffer saline (PBS) were perfused in the
ascending aorta, followed by 500 ml of ice-cold fixative (0.1 M
phosphate buffer (PB) containing 4% (w/v) paraformaldehyde,
pH 7.2–7.4). After post-fixation in the same solution for 2–4 h,
the lumbar segments of the spinal cord and DRG (L4–L5)
were removed and placed in a 30% (w/v) sucrose solution
for 24 h at 4◦C. The sagittal serial sections (30 µm in
thickness for L4–L5 spinal segments) and horizontal sections
(20 µm in thickness for the DRG) were cut using a freezing
microtome (Leica CM1950; Heidelberg, Germany) and collected
into 0.01 M PBS (floating sections). After incubating in a
blocking solution (10% (v/v) normal donkey serum) for 1 h at
room temperature (RT), the sections were incubated with the
following antibodies in sequence (antibodies shown in Table 1):
(1) primary antibodies for 48 h (for single and double staining)
or 72 h (for triple staining) at 4◦C; (2) secondary antibodies
for 4–6 h at RT; and (3) FITC-labeled avidin D (for single
and double staining) or Alexa Fluor 594-labeled avidin D
(for triple staining) for 2 h at RT. Some other sections were
used as controls by replacing the primary antibodies with the
combinations of normal serum according to the species of the
primary antibodies used, while keeping the other conditions
unchanged. Between the steps, the slices were rinsed with 0.01 M
PBS for 30 min. After all steps, the slices were mounted onto
glass slides, coverslipped with 50% glycerol, and conserved at
4◦C.
Quantification of Immunoreactivity
The amount of NK1R internalization was quantified as
previously described (Abbadie et al., 1997; Trafton et al.,
1999, 2001; Riley et al., 2001). In lamina I of the SDH, the
NK1R-positive neurons that included the nucleus and a large
TABLE 1 | Antibodies used in immunofluorescent staining.
Antigens Primary antibodies Secondary antibodies Tertiary antibodies
Single
staining
NK1R or rabbit anti-NK1R antibody (1:200) (S8305;
Sigma-Aldrich, St. Louis, MO, USA)
biotinylated donkey anti-rabbit IgG (1:500)
(AP182F; Millipore, Billerica, MA, USA)
FITC-labeled avidin D (1:1000) (A-2001;
Vector, Burlingame, CA, USA)
MOR rabbit anti-MOR antibody (1:500) (ab10275;
abcam, Cambridge, MA, USA)
Alexa Fluor 594- avidin D (1:1000) (S32356;
Invitrogen, Carlsbad, CA, USA)
Double
staining
NK1R and rabbit anti-NK1R antibody (1:200) (S8305;
Sigma-Aldrich, St. Louis, MO, USA)
biotinylated donkey anti-rabbit IgG (1:500)
(AP182F; Millipore, Billerica, MA, USA)
FITC-labeled avidin D (1:1000) (A-2001;
Vector, Burlingame, CA, USA)
FOS mouse anti-c-Fos antibody (1:500)
(ab11959; abcam, Cambridge, MA, USA)
Alexa Fluor 594 donkey anti-mouse IgG
(1:500) (A-21203, Invitrogen, Carlsbad, CA,
USA)
Triple
stainning
MOR and rabbit anti-MOR antibody (1:500) (ab10275;
abcam, Cambridge, MA, USA)
biotinylated donkey anti-rabbit IgG (1:500)
(AP182F; Millipore, Billerica, MA, USA)
Alexa Fluor 594- avidin D (1:1000) (S32356;
Invitrogen, Carlsbad, CA, USA)
SP and guinea pig anti-Substance P antibody
(1:200) (ab10353; abcam, Cambridge, MA,
USA)
Alexa Fluor 488 donkey anti-guinea pig IgG
(1:500) (706-545-148; Jackson West
Grove, PA, USA)
NeuN mouse anti-NeuN antibody (1:500)
(NG1715199; Millipore, Billerica, MA, USA)
Alexa Fluor 647 donkey anti-mouse IgG
(1:500) (A31571; Invitrogen, Carlsbad, CA,
USA)
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area of cytoplasm were selected. NK1R-positive neurons with 10
or more endosomes in the soma were considered as internalized
neurons (Zhang et al., 2013). The ability of NK1R internalization
was represented as the proportion of NK1R-internalized cells
(NK1R-internalized cells/NK1R-positive cells). Neurons from
four sagittal sections were counted from each rat, and there were
four rats in each group.
Quantification of FOS and NK1R double-labeling was
performed according to previous studies (Trafton et al.,
1999; Riley et al., 2001). The number of FOS-positive cells,
NK1R-positive cells and NK1R/FOS double-labeled cells within
lamina I of the SDH were counted independently. Counts were
obtained from four sagittal sections per rat and presented as the
average numbers per 300 µm sagittal section.
For quantitative analysis of triple labeling in the DRG, we
counted positive cell bodies of SP,MOR and SP/MOR-expressing
neurons. Only the neurons crossing nuclei were selected to count
(Cui et al., 2014). The percentages of single-labeled neurons out
of NeuN-positive neurons and that of double-labeled neurons
out of MOR-like immunoreactivity (MOR-LI) or SP-LI neurons
were calculated. Four sections were obtained from each rat. There
were four rats in each group. Optical density of MOR-LI within
the SDH was measured using the software ‘‘Image-Pro Plus 6.0’’.
Confocal Images
All confocal images were taken with a confocal laser scanning
microscope (FV1000; Olympus, Tokyo, Japan). For NK1R
labeling, all images were taken from sagittal sections of
L4–L5 spinal segments and generated by superimposition of
three optical sections. For MOR labeling, the images were taken
from horizontal sections of the DRG or coronal sections of
the spinal cord. Images were processed using Adobe Photoshop
CS2 to adjust the contrast.
Western Blotting
Rats were deeply anesthetized with 2% pentobarbital
(60 mg/kg, i.p.). The dorsal part of the L4–L5 spinal segments
and L4–L5 DRG were removed immediately and homogenized
in lysis buffer containing proteinase inhibitors and phosphatase
inhibitors (Roche, Switzerland). The protein concentration
was tested using a bicinchoninic acid (BCA) assay (Pierce,
Rockford, IL, USA). Proteins were separated by polyacrylamide
gel electrophoresis. The antibodies used were as follows: rabbit-
anti-MOR antibody (1:1000; ab10275; Abcam), mouse anti-
β-actin antibody (1:5000; A1978; Sigma-Aldrich), peroxidase-
conjugated goat anti-rabbit IgG (1:5000; AP132P; Millipore), and
peroxidase-conjugated goat anti-mouse IgG (1:5000; AP124P;
Millipore). The protein bands were visualized with an enhanced
chemiluminescence (ECL) kit (Pierce, Rockford, IL, USA) and
detected by the ChemiDoc Imaging System (Bio-Rad, Berkeley).
Data Analysis
All the data were presented as the mean ± SEM. Data was
performed using GraphPad Prism 5.01 (San Diego, CA, USA)
for plotting and analysis. Statistical analyses were conducted
using two-way ANOVA and Bonferroni’s post-test for treatment
condition (control vs. drug) for analyzing the effect of EM2 on
pain behaviors, NK1R internalization and FOS expression in
NK1R-positive neurons. Student’s t-test was used for analyzing
the data in the experiments for the establishment of the
DM model and comparing the expression of MORs or SP
in the DRG and SDH. P < 0.05 was considered statistically
significant.
RESULTS
Establishment of the Diabetes Mellitus Rat
Model
STZ-induced diabetic rat is the most commonly used model
in experimental diabetes research (Morrow, 2004). The blood
glucose reached the diabetic level (>16.7 mmol/L, 300 mg/dl)
3 days after STZ injection and was sustained for at least 5 weeks
(Figure 1A). Meanwhile, the body weight did not increase,
further ensuring the establishment of the DMmodel (Figure 1B).
After the onset of DM, five time points (the 7th, 14th, 21st,
28th and 35th day) were selected to test the PWT and PWL.
The diabetic rats began to show obvious mechanical sensitivity
7 days after STZ injection, which continued until the 35th d of
DM (Figure 1C). In parallel, a dramatic thermal hyperalgesia to
noxious plantar heat stimulation was observed in diabetic rats
(Figure 1D). Subsequent experiments were performed 4 weeks
after the STZ injection.
EM2 Exhibited a Lower Antinociceptive
Efficacy in the DNP Rats
According to prior studies (Przewlocka et al., 1999; Przewlocki
et al., 1999), a 2-fold increase in dose is adopted in our
study, which could reveal the different analgesic effects of
EM2 in these two pain models. The data showed intrathecal
(i.t.) delivery of EM2 exhibited dose-dependent analgesic effects
on both the mechanical allodynia and thermal hyperalgesia
of the DNP rats (Figures 2A,B). In rats with mechanical
allodynia, the potent analgesic dose of EM2 was 50 µg instead
of 10 µg or 20 µg, which reached its peak at the 10 min
(P < 0.05), lasted for at least 10 min and disappeared 30 min
after EM2 injection (Figure 2A). Similarly, 50 µg was the
minimum dose of EM2 that eliminated thermal hyperalgesia
(Figure 2B). In addition, tests were conducted in the CFA
inflammatory pain model as the control; EM2 showed a similarly
potent antinociceptive effect, but the potent analgesic dose was
20 µg (Figures 2C,D). Taken together, EM2 had a transient,
dose-dependent analgesic effect in both DNP and CFA rats,
but the analgesic effects of EM2 were impaired in the DNP
model.
EM2 Inhibition of SP Release Was
Hampered in the DNP Rats
Basal and Evoked NK1R Internalization in the DNP
Rats were Identical to the Control Rats
Prior to clarifying the effects of EM2 on SP release from
primary afferent terminals in the DNP rats, we tested the
Frontiers in Molecular Neuroscience | www.frontiersin.org 4 January 2017 | Volume 9 | Article 167
Wan et al. Substance P and MOR in Diabetic Neuropathic Pain
FIGURE 1 | Diabetes mellitus (DM) rat model induced by streptozotocin injection. The diabetic rats exhibited high blood glucose values (A), reduced body
weights (B), decreased paw withdrawal threshold (PWT) (C) and paw withdrawal latency (PWL) (D). n = 6/group. ∗p < 0.05, ∗∗p < 0.01 vs. vehicle-control rats.
responses of NK1Rs to different stimulation modalities. Our
results illustrated that the pattern of NK1R-LI was similar
to that described previously (Figure 3; Littlewood et al.,
1995; Abbadie et al., 1997). In rats without stimulation,
most of the NK1R-LI was found on the membrane of
somas and dendrites (i.e., ‘‘non-internalized’’) in lamina I,
and only a small fraction exhibited signs of internalization
(Figures 4A,B). There was no significant difference in the
control and DNP groups (17.85 ± 2.09% vs. 19.8 ± 1.2%;
F = 3.019, P = 0.521; Figure 4I). Numerous NK1R-internalized
cells were observed in the two groups (88.4 ± 2.14%
vs. 82.5 ± 2.61%; F = 1.489, P = 0.204) 10 min after
SP injection (Figures 4C,D,J). After clamping hindpaws
for 30 s, although there was an obvious decline in the
ratio of NK1R internalization in DNP rats, there was no
significant difference between the two groups (56.3 ± 3.35%
vs. 45.1 ± 3.8%; F = 1.287, P = 0.128; Figures 4E,F,K).
The same situation occurred in the two groups of rats
treated with noxious thermal stimuli (66.86 ± 2.78% vs.
69.1 ± 6.43%; F = 6.201, P = 0.734; Figures 4G,H,L).
All of these results implied that there was no significant
change in basal and evoked SP signaling activity between
control and DNP rats with the different stimulation
modalities.
EM2 Inhibition of SP Release was Impaired in the
DNP Rats
To determine the role of SP signaling during the EM2 analgesic
process, we observed the effects of a potent dose of EM2 onNK1R
internalization induced by noxious stimulation. Since previous
data suggested that opioids suppressed SP release effectively
in inflammation pain (Chen et al., 2014), we evaluated NK1R
internalization in CFA rats as a parallel control group. The results
illustrated that EM2 significantly decreased the proportion of
NK1R internalization induced by noxious thermal stimulation
in vehicle-control (66.86 ± 2.78% vs. 42.85 ± 1.15%; F = 5.888,
P = 0.009; Figures 5A,B, 6B) and CFA rats (80.88 ± 3.32%
vs. 40.28 ± 4.61%; F = 1.932, P = 0.006; Figures 5C,D, 6B).
However, in the DNP rats, this inhibitory influence of EM2
on SP release disappeared (69.1 ± 6.43% vs. 60.7 ± 2.94%,
F = 5.561, P = 0.393; Figures 5E,F, 6B). Similar tendency of
changes of NK1R internalization appeared in these three groups
of rats treated with noxious mechanical stimulation (Figure 6A).
The results demonstrated that the inhibitory effects of EM2
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FIGURE 2 | The analgesic effects of endomorphin-2 (EM2) on mechanical allodynia and thermal hyperalgesia were impaired in the diabetic
neuropathic pain (DNP) rats. On the 28th day of DM, intrathecal injection of EM2 exhibited dose-dependent analgesic effects on both mechanical allodynia (A)
and thermal hyperalgesia (B) in the DNP rats. The most potent effect was observed 10 min after injection and lasted for 10–20 min. Three days after complete
Freund’s adjuvant (CFA) injection, EM2 dose-dependently decreased the PWT (C) and PWL (D) in the inflammation rats. The most potent dose was 50 µg and
20 µg in the DNP and CFA rats, respectively. n = 4/group. ∗p < 0.05, ∗∗p < 0.01, vs. saline-injected rats.
on NK1R internalization induced by both of the two noxious
stimulation were impaired in the DNP but not in the control
and CFA rats.
EM2 was Unable to Affect Exogenous SP-Induced
NK1R Internalization
NK1R internalization not only provides a measure of presynaptic
SP release, but also provides a functional measure of SP signaling
(Trafton et al., 1999; Riley et al., 2001). To test whether
EM2 directly affects the internalization of NK1R, we observed
the effect of EM2 onNK1R internalization induced by exogenous
SP in DNP rats. The present results showed that compared to
saline-injection rats (Figure 7A), SP (i.t., 30 nM) induced a
significant NK1R internalization within the superficial layers of
the SDH (82.5 ± 2.61%, Figure 7B), which was not affected
by injection of EM2 (i.t., 50 µg, 10 min before SP injection;
81.62 ± 2.86%, F = 1.201, P = 0.828; Figure 7C) but was
decreased by L732138 (i.t., 100 nM, 10 min before SP injection;
Cahill and Coderre, 2002; Zhang et al., 2013; Figure 7D). These
results indicated that EM2 had no direct effects on NK1R
internalization.
EM2 Failed to Reduce FOS Expression in
the NK1R-Positive Neurons in DNP Rats
A combination of FOS and NK1R staining was further used
to test the effects of EM2 on NK1R-positive neurons. The
results illustrated that in the DNP rats after mechanical
stimulation, approximately 70% of the NK1R-LI cells also
expressed FOS, while only about 10% of Fos-LI neurons were
NK1R-positive neurons (Figure 8A, Table 2). EM2 reduced
the number of FOS-expressing neurons in the SDH but
not that of NK1R-positive and NK1R-FOS double-labeled
cells (Figure 8B, Table 2). The same situation occurred
in the DNP rats after thermal stimulation (Figures 8C,D,
Table 2).
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FIGURE 3 | Basal and substance P (SP)-evoked neurokinin-1 receptor (NK1R) internalization within the spinal dorsal horn (SDH). Confocal images
illustrate the dorsoventral pattern of NK1R-like immunoreactivity (NK1R-LI) within the SDH in a naive (A) and a SP-treated (B) rat. NK1R-LI was distributed on the
membrane of the soma and dendrites in lamina I (i.e., “non-internalized”; A, a1, a2). NK1R-LI was present as bright, immunofluorescent endosomes in the cytoplasm
of the soma and dendrites (i.e., “internalized”; B, b1, b2) throughout the dorsal horn, and was most prominent in lamina I. NK1R non-internalized and internalized
neurons are indicated with a “4” and “F”, respectively. Scale bar = 100 µm (A,B), 20 µm (a1–b2).
DNP Reduced the Expression of MORs in
the Primary Sensory Neurons and Their
Central Terminals
MORs localized in primary central terminals mediates
EM2 analgesia in the spinal cord. The loss of EM2 inhibition
of SP release in DNP might be caused by the decrease in
MOR expression in the DRG neurons. To test whether
this is the case, we measured the level of MOR proteins in
the DGR and spinal cord. The WB analysis illustrated that
the expression of MOR proteins in DNP rats decreased
to 66.8 ± 5.82% in the spinal cord (Figures 9A,D)
and 51.77 ± 5.18% in the DRG (Figures 9B,E) of that
in the control. This result was further confirmed by
MOR labeling in the SDH (71.77 ± 2.42% to control;
Figures 9C,F) and DRG (35.68 ± 2.84% vs. 22.75 ± 2.27%,
F = 1.579, P = 0.012; Figures 9G,I). To reveal the change
in MORs in the SP-LI neurons, we then performed
triple staining for MOR, SP and NeuN in the DRG.
The results illustrated that there was no difference in
the proportion of SP-LI cells between the control and
DNP rats (Figures 9G,H). However, the expression of
MOR-LI in SP-ergic neurons was reduced in DNP rats
(78.26 ± 6.09% vs. 60.57 ± 2.66%, F = 5.242, P = 0.037;
Figure 9J).
DISCUSSION
Spinal EM2 Analgesia in the DNP Rats
Together with EM-1, EM-2 (Tyr-Pro-Phe-Phe-NH2) is
considered as an endogenous MOR ligand since it was one
of the first peptides isolated from brain binding to MOR
with high affinity and selectivity (Zadina et al., 1997). EM2-ir
is primarily restricted to the superficial lamina of the SDH,
where it plays the analgesic role in suppressing pathological
pain (Sakurada et al., 1999, 2001). EM2 could be an ideal
substitute for traditional morphine-like opioids owing to
its remarkable antalgic properties and less adverse effects
than opioids (Czapla et al., 2000; Varamini et al., 2013).
What’s more, the mechanisms underlying EM2 analgesia
may be more complicated. Bearing similarity to opioids,
EM2 activates both pre- and postsynaptic MORs, leading
to presynaptic inhibition of excitatory neurotransmitters
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FIGURE 4 | No significant changes in basal and evoked NK1R internalization between the control and DNP rats. The confocal images illustrate basal
(A,B) and evoked (C–H) NK1R internalization within superficial lamina of the SDH by different stimulation modalities. (A,B) Non-stimulus; (C,D) SP treatment
(i.t., 30 nM); (E,F), 30 s clamping; (G,H), hot stimulus (50◦C, 1 min). Statistical analysis for NK1R-LI showed that there were no differences in basal (I) and evoked
NK1R (J–L) internalization between the two groups. n = 4/group. Scale bar = 100 µm.
(glutamate, SP and CGRP) release (Soldo and Moises, 1998;
Leng et al., 2005; Heinke et al., 2011) and postsynaptic
hyperpolarization of excitatory interneurons (Wu et al.,
2003; Fujita and Kumamoto, 2006; Chen Y. B. et al.,
2015), respectively. Interestingly, EM2 renders a specific
binding site for SP1–7 (Botros et al., 2006, 2008; Fransson
et al., 2010), a major bioactive metabolite of SP, and may
mediate the antinociceptive effects of SP1–7 in pathological
pain (Jonsson et al., 2015). More importantly, EM2 and
morphine dissimilarly modulated MOR mRNA expression
and function (McConalogue et al., 1999; Yu et al., 2003).
Recently, pharmacologically modified endomorphin analogs
aiming at enhancing its membrane permeability and resilience
to enzymatic degradation have been developed which are
prospective to proceed from research to the pharmaceutical
industry (Varamini and Toth, 2013; Janecka and Gentilucci,
2014).
Our previous study suggested that the decreased expression
of EM2 and MOR in the spinal cord was related to the
progress of painful diabetic neuropathy (Kou et al., 2016).
In the present study, we evaluated the analgesic efficacy of
exogenous EM2 in DNP. Our behavioral testing showed that
EM2 alleviated both mechanical and thermal hyperalgesia
in the DNP and CFA rats. Concerning the antinociceptive
effects of EM2 in inflammatory pain, it has been reported
that EM2 dose-dependently increased the tail-flick latency in
formalin-induced pain and a dose of 10 µg was enough to
generate analgesic effects (Przewlocka et al., 1999). However,
the potent dose of EM2 was higher (20 µg) in our experiment,
which may result from the discrepancy in pain model (acute
or chronic inflammatory pain) and behavioral measurement
(tail flick test or von Frey filaments; Przewlocka et al.,
1999). Importantly, comparing to the CFA model, the DNP
rats required a significantly higher dose of EM2 to exhibit
analgesic effects, suggesting that EM2 analgesic efficacy is
impaired. Opioid resistance is a common phenomenon in
the treatment of DNP. In patients with diabetic neuropathy,
high doses of opioids (tramadol and oxycodone) were needed
to gain equivalent pain-relieving effects (Harati et al., 2000;
Watson et al., 2003). In rodent models of STZ-induced
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FIGURE 5 | The inhibitory effect of EM2 on NK1R internalization evoked by thermal stimuli was impaired in the DNP rats. The confocal images of NK1R
labeling in lamina I illustrate the changes in NK1R internalization after EM2 injection (i.t.) in the control (POD 28 days; A,B), CFA (POD 3 days; C,D) and DNP
(POD 28 days; E,F) rats. There was a decrease in number of NK1R-internalized cells in control (B) and CFA (D) but not in DNP (F) rats after EM2 administration.
Saline injection (10 µl; A,C,E). EM2 injection (50 µg; B,F). EM2 injection (20 µg; D). NK1R non-internalized and internalized neurons are indicated with a “4” and
“F”, respectively. Scale bar = 100 µm (shown in D for A–D), 20 µm (shown in f3 for a1–f3).
diabetic neuropathy, the antinociceptive efficacy of opioids
after systemic (Courteix et al., 1998), spinal (Chen and Pan,
2003; Mousa et al., 2013; Shaqura et al., 2013) or supraspinal
(Zurek et al., 2001) administration is reduced relative to
controls.
No Changes in Basal and Evoked SP
Signaling in the DNP Rats
The neuropeptide SP, one of the most important pain mediators,
is synthesized in small-sized DRG neurons and contributes
to the development of chronic pain by activating the NK1R
(Mantyh et al., 1997; Cahill and Coderre, 2002; Marvizón
et al., 2003). In the present study, we examined the change
in basal and evoked NK1R internalization within lamina I
in the condition of DNP. In rats without stimulation, there
was no significant change in NK1R internalization in DNP
rats compared to the control, suggesting that the baseline
SP release from peptidergic fibers was not changed. This
was consistent with microdialysis data showing that the basal
level of SP in spinal cerebrospinal fluid was not different in
diabetic and control rats (Calcutt et al., 2000). Similarly, in
rats with both mechanical and thermal stimuli, there were
no significant changes in the amounts of internalized neurons
between the two groups, indicating that evoked presynaptic SP
release from the peptidergic fibers was not changed, either.
However, striking discrepancies existed among our data and
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FIGURE 6 | EM2 decreased the level of NK1R internalization evoked by noxious stimulation in the DNP but not in the non-diabetic rats. The bar graphs
show that a potent analgesic dose of EM2 decreased the numbers of NK1R-internalized cells in the control and CFA but not DNP rats under the condition of both
mechanical (A) and thermal (B) stimuli. 4–6 slices from a rat. n = 4–5/group. ∗∗p < 0.01.
prior studies. Paw formalin injection attenuated SP-LI levels
in spinal cord dialysates (Calcutt et al., 2000), while in vitro
K+ administration evoked an excessive release of SP from
the spinal cord in diabetic rats (Kamei et al., 1991). These
differences might be derived from the heterogeneity of these
studies (in vitro or in vivo, stimulation modality and detective
FIGURE 7 | EM2 had no direct influence on exogenous SP-induced NK1R internalization. Representative confocal images illustrate that exogenous
SP-induced NK1R internalization was inhibited by pretreatment with L-732138 instead of EM2 in the DNP rats. (A) 10 µl saline; (B) 30 nM SP (i.t.); (C) pretreatment
with 50 µg EM2 (i.t.) 10 min before 30 nM SP (i.t.); (D) pretreatment with 100 nM L-732138 (i.t.) 10 min before 30 nM SP (i.t.). NK1R non-internalized and internalized
neurons are indicated with a “4” and “F”, respectively. n = 4/group. Scale bar = 100 µm (shown in D for A–D), 20 µm (shown in d2 for a1–d2).
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FIGURE 8 | EM2 decreased FOS-LI but not NK1R-LI and FOS/NK1R
double-labeled neurons within the SDH in the DNP rats. The NK1R
(green) and FOS (red) double-staining images illustrated that EM2 decreased
FOS-expressing neurons but not FOS/NK1R double-labeled neurons within
lamina I of the SDH. (A,C) Pretreatment with 10 µl saline; (B,D) pretreatment
with 50 µg EM2. n = 3–4/group. Scale bars = 50 µm.
method). However, our results were in agreement with another
study suggesting that dorsal root stimulation failed to influence
NK1R internalization in spinal cord slices of CCI rats (Chen et al.,
2014).
The fact that there was no significant change in basal and
evoked presynaptic SP release suggested that the SP signaling
within lamina I of the SDH was not sensitized in the condition
of diabetic neuropathy. Our previous study has reported the
increased presynaptic glutamate release within the SDH in
DNP rats (Kou et al., 2016). Therefore, SP signaling might
not play an essential role in the central sensitization of painful
diabetic neuropathy and this might account for the inefficacy
of NK1R antagonists in the treatment of DNP (Sindrup et al.,
2006).
SP-NK1R Signaling Was Insusceptible to
Opioid Analgesia in the DNP Rats
The main objective of the present study was to investigate the
inhibitory influence of EM2 on SP release in the DNP rats.
The results illustrated that the analgesic dose of EM2 failed to
reduce the number of NK1R-internalized neurons induced by
noxious stimulation in DNP rats but not in control and CFA rats.
TABLE 2 | Effects of endomorphin-2 (EM2) on FOS/NK1R cells in the
diabetic neuropathic pain (DNP) rats (n = 3–4).
Groups FOS-positive
cells
NK1R-positive
cells
FOS in
NK1R-positive cells
M S + saline 36.64 ± 1.86 5.14 ± 0.59 3.77 ± 0.58
M S + EM2 20.32 ± 2.54 5.02 ± 1.02 3.45 ± 1.14
T S + saline 39.72 ± 5.91 5.25 ± 1.54 4.26 ± 1.25
T S + EM2 19.95 ± 4.36 5.38 ± 1.13 4.15 ± 1.53
MS, mechanical stimulus; TS, thermal stimulus.
Similarly, a loss of the inhibition of SP release by DAMGO has
been reported in the CCI model (Chen et al., 2014). Considering
that opioids had better analgesic effects in CFA and control rats
than in DNP and neuropathic pain rats (Przewlocka et al., 1999;
Mousa et al., 2013; Shaqura et al., 2013; Zhang et al., 2016),
the loss of inhibition of SP release may contribute to opioid
resistance in chronic neuropathic pain.
A combination of FOS and NK1R labeling is a good way
to evaluate the activity of SP-NK1R signaling (Trafton et al.,
1999; Riley et al., 2001). In DNP rats, EM2 reduced FOS
expression in the SDH but not in NK1R-positive neurons,
indicating that the SP nociceptive pathway was insusceptible
to EM2 analgesia in the DNP rats. Pretreatment with an
NK1R antagonist but not EM2 blocked exogenous SP-induced
NK1R internalization. This phenomenon, together with the
unchanged number of FOS/NK1R double-labeled neurons after
EM2 administration in DNP rats, implied that EM2 had no
direct effect on NK1R-internalized neurons. The fact that
there was no expression of MORs in NK1R neurons (Spike
et al., 2002; Song and Marvizon, 2003) also excluded the
possibility of a postsynaptic mechanism of EM2 to inhibit SP
signaling.
Previous studies have provided possible mechanisms
underlying the incapability of opioids in suppressing presynaptic
SP release. Neurokinin release from central terminals is
controlled by numerous presynaptic modulatory receptors,
including inhibition by GABAB (Marvizón et al., 1999; Riley
et al., 2001; Zhang et al., 2010), α2-adrenergic (Takano et al.,
1993) and opioid (Kondo et al., 2005; Beaudry et al., 2011; Chen
et al., 2014) receptors, and facilitation by capsaicin (Marvizón
et al., 2003), serotonin (Inoue et al., 1997) and NMDA (Liu et al.,
1997; Trafton and Basbaum, 2000) receptors. In the condition of
DNP, the overexpression of NMDA receptors (Tomiyama et al.,
2005; Rondon et al., 2010) and decreased function of GABAB
(Wang et al., 2007) at the primary afferent terminals mobilizes
excessive SP release (Marvizón et al., 1999) and counteracts the
effects of EM2. In the present study, we provided evidence that
the decreased level of presynaptic MORs might account for the
reduced efficacy of EM2 on SP release.
Down-Regulation of MORs Contributes to
Lower Opioid Analgesic Efficacy
The MOR in primary terminals plays an important role in
opioid analgesia (Kohno et al., 2005; Chen and Pan, 2006).
Indeed, the down regulation of MORs has been found in
many opioid-resistant neuropathological pain models (Chen
et al., 2002; Cahill et al., 2003; Kohno et al., 2005; Mousa
et al., 2013; Shaqura et al., 2013, 2014). The present study
demonstrated reduced expression of MOR-LI fibers within
the SDH, which was probably owing to the loss of MOR/SP
double-staining sensory neurons. Here, a hypothesis for the
effects of exogenous EM2 on SP signaling within the SDH in
painful diabetic neuropathy was proposed: compared to the
normal condition, SP-NK1R signaling within lamina I was
not sensitized in the case of DNP during nociceptive message
transmission; In addition, SP-NK1R signaling activated by
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FIGURE 9 | Reduced expression of µ-opioid receptors (MORs) in neurons of the dorsal root ganglion (DRG) and SDH in the DNP rats. Western blot
(WB) bands illustrated that the level of MORs was decreased in the SDH (A) and DRG (B) of the DNP rats. Statistical analysis of the level of MORs within the SDH
(D) and DRG (E). Immunohistochemistry (IHC) results showed that there was a decrease of MOR labeling within the SDH in the DNP rats (C). Statistical analysis of
the expression of MORs within the SDH (F). Triple labeling of SP (green), MOR (red) and NeuN (blue) in the DRG slices showed that the expression of MOR-like
immunoreactivity (MOR-LI) but not SP-like immunoreactive (SP-LI) neurons in the DRG was reduced in the DNP rats. Meanwhile, the expression of MORs in
SP-positive cells was also reduced (G). Quantitative analysis of the numbers of SP-LI neurons (H), MOR-LI neurons (I) and SP/MOR double-labeled neurons (J) in
the DRG of the control and DNP rats. Four slices from each rat were used for immunofluorescent staining, n = 4/group. ∗p < 0.05, ∗∗p < 0.01, vs. vehicle-control
rats. Scale bar = 100 µm.
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noxious stimuli was insusceptible to exogenous EM2, probably
owing to the loss of presynaptic MORs in the condition of
diabetic neuropathy.
Sensory neuron apoptosis might not be a primary cause of
the loss of MOR-LI terminals since there was no change in the
total number of DRG neurons in STZ-treated rats (Zochodne
et al., 2001). Instead, MOR displacement from the membrane
to perinuclear compartments was responsible for the loss of
presynaptic MOR expression within the SDH (Mousa et al.,
2013). In addition to the loss of MOR expression, the impairment
of MOR-G protein coupling and the reduction in G protein
subunits have also been reported to be correlated with morphine
insensitivity in DNP rats (Chen and Pan, 2003; Hajializadeh
et al., 2010). These changes also occurred in injury-induced
neuropathic pain (Zhang et al., 1998). However, in inflammatory
pain, up-regulated MOR expression on peripheral sensory
neurons potentiated opioid antinociception (Mousa et al., 2007).
Thus, the variety of MOR signaling function determines the
analgesic efficacy of opioids in different types of pathological
pain.
Apart from the loss of control of SP release, decreased
presynaptic MOR expression could also lead to decreased opioid
efficacy via other mechanisms. Our previous study indicated
that decreased presynaptic MOR expression led to attenuated
inhibition on presynaptic glutamate release by EM2 during
STZ-induced diabetes (Kou et al., 2016). Moreover, a loss in
functional MORs on DRG neurons was a contributing factor
to the impaired opioid inhibitory effects on capsaicin-induced
TRPV1 activity in DNP rats (Shaqura et al., 2014). Considering
this, current measures concerning the promotion of MOR
signaling provide a promising orientation to facilitate opioid
analgesia (Cahill et al., 2003; Mousa et al., 2007, 2013; Shaqura
et al., 2013). Importantly, long-term EM2 administration in the
early stages of DNP partially recovered the diminished spinal
MOR expression and ameliorated painful diabetic neuropathy
(Kou et al., 2016). Therefore, although a single dose of EM2 as
the present study showed, exhibited lower analgesic effects,
long-term EM2 pharmacotherapy may be a hopeful strategy in
the field of clinical DNP management.
In addition to neural mechanisms, glial factors also
contributed to reduced opioid efficacy as well as its side effects,
namely, OT and OIH. On one hand, excessive inflammatory
factors released by hyperactive microglia in the condition of
neuropathic pain (Ji et al., 2013)may impede opioid efficacy since
microglia inhibitors could increase morphine analgesia (Posillico
et al., 2015; Castany et al., 2016); on the other hand, opioids
activate microglia and astrocytes which in turn aggravates pain,
and interrupting neuron-glia interaction could prevent tolerance
and OIH (Mika, 2008; Grace et al., 2016; Roeckel et al., 2016). In
light of these, a combination of endomorphin and glial inhibitors
may be a novel and promising method for the treatment of
neuropathic pain.
CONCLUSION
In summary, our findings showed that SP-NK1R signaling is
refractory to EM2 analgesia in STZ-induced diabetic rats. The
diminished inhibition of EM2 might be attributed to reduced
expression of presynaptic MORs. This might account for the
impaired analgesic efficacy of opioids in the treatment DNP.
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